The FDA's perspective on the risk for rapid rise in hemoglobin in treating CKD anemia: Quo Vadis

Clin J Am Soc Nephrol. 2010 Apr;5(4):553-6. doi: 10.2215/CJN.00490110. Epub 2010 Mar 4.
No abstract available

Publication types

  • Editorial

MeSH terms

  • Anemia / blood
  • Anemia / drug therapy*
  • Anemia / etiology
  • Chronic Disease
  • Consumer Product Safety
  • Drug Labeling
  • Evidence-Based Medicine
  • Hematinics / adverse effects
  • Hematinics / therapeutic use*
  • Hemoglobins / metabolism*
  • Humans
  • Kidney Diseases / blood
  • Kidney Diseases / complications
  • Kidney Diseases / therapy*
  • Practice Guidelines as Topic
  • Risk Assessment
  • Risk Factors
  • Treatment Outcome
  • United States
  • United States Food and Drug Administration*
  • Up-Regulation

Substances

  • Hematinics
  • Hemoglobins